tert-butyl (4-(2-hydroxyethyl)piperidin-1-yl)carbamate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl (4-(2-hydroxyethyl)piperidin-1-yl)carbamate
• 英文别名: 2(N-t-Butyloxycarbonylaminopiperidin-4-yl)ethanol；tert-butyl N-[4-(2-hydroxyethyl)piperidin-1-yl]carbamate
• 化学式: C₁₂H₂₄N₂O₃
• 分子量: 244.334
• InChiKey: LENXDIBYIFWROC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  61.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (4-(2-hydroxyethyl)piperidin-1-yl)carbamate 在 4-二甲氨基吡啶 、 三乙胺 、 N,N-二异丙基乙胺 、 sodium iodide 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 51.0h， 生成 3-(4-(4-(2-(1-aminopiperidin-4-yl)ethyl)piperazin-1-yl)-3-fluorophenyl)piperidine-2,6-dione trifluoroacetate
  参考文献：
  名称：

  [EN] NOVEL PLK1 DEGRADATION INDUCING COMPOUND
  [FR] NOUVEAU COMPOSÉ INDUISANT LA DÉGRADATION DE PLK1

  摘要：

  The present disclosure relates to a novel PLK1 degradation inducing compound, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.

  公开号：

  WO2023017446A1
• 作为产物：
  描述：

  1-nitroso-4-piperidinethanol 在 溶剂黄146 、 sodium hydroxide 、 锌 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 18.0h， 生成 tert-butyl (4-(2-hydroxyethyl)piperidin-1-yl)carbamate
  参考文献：
  名称：

  [EN] NOVEL PLK1 DEGRADATION INDUCING COMPOUND
  [FR] NOUVEAU COMPOSÉ INDUISANT LA DÉGRADATION DE PLK1

  摘要：

  The present disclosure relates to a novel PLK1 degradation inducing compound, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.

  公开号：

  WO2023017446A1

文献信息

• Fibrinogen receptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US05525617A1

  公开（公告）日：1996-06-11

  Fibrinogen receptor antagonists having the formula ##STR1## for example ##STR2##

  具有以下公式的纤维蛋白原受体拮抗剂 ##STR1## 例如 ##STR2##。
• US5525617A
  申请人：——

  公开号：US5525617A

  公开（公告）日：1996-06-11
• [EN] 3-SUBSTITUTED INDOLES AS CHEMOKINE ANTAGONISTS<br/>[FR] INDOLES SUBSTITUES EN 3EME POSITION SERVANT D'ANTAGONISTES DE CHIMIOKINE
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO2002079190A1

  公开（公告）日：2002-10-10

  A compound of the formula (I): in which: R1 is (C¿1-6?)alkyl, optionally substituted aryl or optionally substituted heteroaryl; R?2 and R3¿ which may be the same or different are selected from the group consisting of hydrogen, halogen, cyano(C¿1?-6)alkyl, (C3-7)cycloalkyl, (C1-6)alkoxy, halo(C1-6)alkyl, hydroxy, amino, mono- or di-(C1-6)alkylamino, acylamino, nitro, carboxy, (C1-6)alkoxycarbonyl, (C1-6)alkenyloxycarbonyl, (C1-6)alkoxycarbonyl(C1-6)alkyl, carboxy(C1-6)alkyl, (C1-6)alkylcarbonyloxy, carboxy(C1-6)alkyloxy, (C1-6)alkoxycarbonyl(C1-6)alkoxy, (C1-6)alkylthio, (C1-6)alkylsulphinyl, (C1-6)alkylsulphonyl, sulphamoyl, mono- and di-(C1-6)-alkylsulphamoyl, carbamoyl, mono- and di-(C1-6)alkylcarbamoyl, ureido, (C1-6)alkylsulphonamido, arylsulphonamido, aryl, aryl(C1-6)alkyl, aryl(C1-6)alkoxy, aryloxy and heterocyclyl; R?4¿ is hydrogen or C¿(1-6)?alkyl; R?5 and R6¿ which may be the same or different are hydrogen or C¿(1-6)?alkyl, or together with the carbon atoms of the ring to which they are attached from the bridging 5- to 7 membered ring; W is a bond, C(1-6)alkylene optionally substituted by C(1-6)alkyl, CH2O, CH2S OR trans-(E)-CR?7¿=CH-Y- in which R7 is hydrogen or (C¿1-6?)alkyl and Y is a bond, trans-(E)-CH=CH-, or CO; m and n are each integers from 1 to 3; p and q are each independently 1 or 2; and x is an integer from 1 to 4; or a pharmaceutically acceptable salt thereof. For use in the manufacture of a medicament for use in the treatment of inflammatory conditions with monocyte and/or lymphocyte involvement.
• 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS
  申请人：[en]UPPTHERA, INC.

  公开号：WO2024155112A1

  公开（公告）日：2024-07-25

  Novel 2,4-Dianilinopyrimidine-based Aurora-A kinase (AURKA) degraders are disclosed. The present AURKA degraders are proteolysis targeting chimeras (PROTACs) that recruit AURKA protein into optimized CRBN E3 ubiquitin ligase via linkers. The compounds may induce selective AURKA degradation and may be utilized for the treatment of cancer.
• [EN] NOVEL PLK1 DEGRADATION INDUCING COMPOUND<br/>[FR] NOUVEAU COMPOSÉ INDUISANT LA DÉGRADATION DE PLK1
  申请人：[en]UPPTHERA, INC.

  公开号：WO2023017446A1

  公开（公告）日：2023-02-16

  The present disclosure relates to a novel PLK1 degradation inducing compound, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.